



PTO/SB/08b (01-08)

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete If Known	
				Application Number	10/714,449-Conf. #9366
				Filing Date	November 17, 2003
				First Named Inventor	Laguens
				Art Unit	1633
				Examiner Name	S. Kaushal
Sheet	1	of	1	Attorney Docket Number	42597-193226

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Kastrup et al., "Direct Intramyocardial Plasmid Vascular Endothelial Growth Factor-A ₁₆₅ Gene Therapy in Patients with Stable Severe Angina Pectoris", JACC, 45(7), 2005, pp. 982-988		
	C2	Vera Janavel et al., "Plasmid-mediated VEGF gene transfer induced cardiomyogenesis and reduces myocardial infarct size in sheep", Gene Therapy, 2006, pp. 1-10		
	C3	Stewart/Cannon, "NORTHERN: A Prospective, Randomized, Double Blind, Placebo-Controlled Evaluation of Intramyocardial VEGF-165 Plasmid Gene Therapy in Patients with Refractory Angina", Transcatheter Cardiovascular Therapeutics conference, Cardiovascular Research Foundation, October 23, 2007, Abstract		
	C4	Lekas et al., Growth factor-induced therapeutic neovascularization for ischaemic vascular disease: time for a re-evaluation", Therapeutic neovascularization for ischaemic vascular disease, Current Opinion in Cardiology 21, pp. 376-383		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--